Navigation Links
First Swiss Patients Treated with the Percutaneous MitraClip(R) System

Use of the MitraClip(R) System Continues to Expand in the European Union

MENLO PARK, Calif., March 10 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today that the first series of patients have been successfully treated with the MitraClip(R) system at the Cardiocentro Ticino in Lugano, Switzerland. The MitraClip(R) system is the only medical device commercially available in the European Union which provides a non-surgical mitral valve repair option for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).

Mitral regurgitation is the most common type of heart valve insufficiency in Europe and the United States, affecting millions of people worldwide. In the vast majority of patients, the MR is untreated, requiring the heart to work harder and ultimately leading to heart failure.

The first patients in Switzerland were treated by the team led by Prof. T. Moccetti, M.D., assisted by G.B. Pedrazzini, M.D.; E. Pasotti, M.D.; F.F. Faletra, M.D.; and A. Auricchio, M.D., Ph.D.

"Until now, many heart failure patients with associated functional MR had no therapeutic options except medical management when surgery was not possible either because they have already had heart surgery, or presented with important renal insufficiency or lung disease, all of which significantly increase the risk of a second or a third operation," said Prof. Moccetti, Head of Cardiology Division and Medical Director of Cardiocentro Ticino. He added "The MitraClip(R) therapy provides a valuable alternative for these patients."

Professor Auricchio, Director of the Heart Failure Clinic commented: "Heart failure is a devastating disease, significantly more common than cancer and has the same poor life-expectancy. Implantable devices such as cardiac resynchronization therapy have improved the quality of life of these patients. Now with percutaneous mitral valve repair, I am confident we can expand our treatment possibilities to many of our Swiss heart failure patients."

Evalve initiated commercial sales of the MitraClip(R) system in Europe under the CE Mark in September 2008. The company is employing a direct sales strategy and is taking a disciplined and measured approach to the initial commercial roll out. The company has worked closely with hospitals to deliver high quality training programs in preparation for the first series of implants. The MitraClip(R) device is now currently being implanted in five countries, including Germany, Italy, the United Kingdom, the Netherlands and now Switzerland.

"We are very pleased to see the successful initial use of the MitraClip device in Switzerland at this important cardiac center," said Ferolyn Powell, president and chief executive officer of Evalve. "The functional MR heart failure patient continues to be the fastest growing segment of the population undergoing treatment with the MitraClip(R) system and the initial commercial results in this population are very encouraging."

About the MitraClip(R) Procedure

Percutaneous mitral repair with Evalve's MitraClip(R) device is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.

About Evalve, Inc.

Founded in 1999, Evalve, Inc., headquartered in Menlo Park, Calif., has developed a proprietary system which enables percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. For more information about Evalve, Inc., and for an animated explanation of the procedure using the MitraClip(R) device, visit Evalve is the first portfolio company from the medical device company incubator, The Foundry (

The MitraClip(R) system is currently undergoing clinical evaluation in the United States and Canada.

MitraClip(R) and Evalve are registered trademarks of Evalve, Inc.

SOURCE Evalve, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
2. A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
5. Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
6. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
7. First U.S. Patients Enrolled in the REALISM Continued Access Study
8. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
9. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
10. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
11. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
Post Your Comments:
(Date:11/27/2015)... UTRECHT , Pays-Bas, November 27, 2015 /PRNewswire/ ... combiner l,immunothérapie au traitement photodynamique au Bremachlorin contre ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    --> Une nouvelle ... au Bremachlorin contre le cancer avancé.    ...
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... 27, 2015 Ein neuer ... Krebs.   --> Ein neuer Kombinationsansatz ...   --> Ein neuer Kombinationsansatz ...   Clinical Cancer Research vom ... Cancer Research vom 6. November 2015 berichtet. ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... out by the University of Toronto and the University of British Columbia suggested that ... for head injuries. The article explains that part of the reason for the controversial ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... safe and convenient way to dispense prescription medications at home, so he invented ... way to monitor and dispense prescription medications. In doing so, it could help ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is ... Pro X. With ProSidebar: Fasion, video editors can easily add an informative sidebar ... minimalist title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A simply groundbreaking ... is an interesting show that delves into an array of issues that are presently ... could benefit from open dialogue, this show is changing the subjects consumers focus on, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
Breaking Medicine News(10 mins):